Active, Not Recruiting Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer NCT04061980 Conditions BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Endocrine Gland Neoplasms, +11 more Locations Providence Portland Medical Center — Portland, Oregon, United States View Trial Details
